Rhinology
CEORL-HNS 2026 | Emerging Evidence of Biologics for the Treatment Landscape of CRSwNP
Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.
BMBCh, DM
Claire Hopkins +1 more
Related resources
Learning objectives
- Understand the pathophysiologic mechanisms of type 2 inflammation in CRSwNP
- Recognize the substantial disease and treatment burdens experienced by patients with uncontrolled CRSwNP
- Review the latest real-world evidence supporting biologic therapies in CRSwNP management
Description
Join experts Eugenio De Corso and Claire Hopkins for an educational symposium on the pathophysiologic mechanisms of type 2 inflammation in CRSwNP, the substantial disease and treatment burdens experienced by patients with CRSwNP, management approaches in recurrent CRSwNP, and the latest real-world evidence supporting biologic therapies in CRSwNP management.
Tags
MAT-US-2605576 v1.0 - P Expiration Date: 06/10/2028
About these experts
